Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RGS4 | P49798 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942848 | 0.64 | RGS4 (0.36) | LMNANR2F2HTTRAB9ASMN1; SMN2 | |
| SCHEMBL3750688 | 0.64 | RAB9A (0.41) | LMNANR2F2HTTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL4940305 | 0.57 | CYP1A1 (0.48) | LMNANR2F2HTTRAB9ASMN1; SMN2 | |
| SCHEMBL9982876 | 0.57 | TNF (0.35) | — | |
| SCHEMBL838929 | 0.51 | RGS4 (0.58) | RGS4 | |
| SCHEMBL9473364 | 0.51 | MAPT (0.47) | LMNARGS4 | |
| SCHEMBL24031478 | 0.49 | RGS4 (0.54) | RGS4 | |
| SCHEMBL4883169 | 0.49 | TSHR (0.50) | LMNASMN1; SMN2RGS4 | |
| SCHEMBL11448924 | 0.49 | HSD11B1 (0.53) | LMNANR2F2HTTRAB9ASMN1; SMN2 | |
| Hexane SCHEMBL8204948 | 0.44 | TSHR (0.78) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735434-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080287510-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287510-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | LMNA 4197/4885NR2F2 768/4885HTT 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.